




APPENDICES

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่

Copyright© by Chiang Mai University
All rights reserved

APPENDIX A

SOLVENTS PREPARATION

The organic solvents were commercial grade and distilled before using for extraction, as eluent for thin layer chromatography and column chromatography.

MEDIA PREPARATION

1. Potato Dextrose Agar (PDA)

- | | |
|-----------------|-------|
| - Sliced potato | 200 g |
| - Glucose | 20 g |
| - Agar | 20 g |

In 1 liter of Reverse osmosis water and autoclaved at 121°C for 15 minutes

2. Transform medium I: Sabouraud Dextrose Broth (SDB)

- | | |
|-----------|------|
| - Glucose | 40 g |
| - Peptone | 10 g |

In 1 liter of Reverse osmosis water and the pH was adjusted to 5.8 before autoclaving at 121°C for 15 minutes

3. Transform medium II: Potato Dextrose Broth (PDB)

- | | |
|-----------------|-------|
| - Sliced potato | 200 g |
| - Glucose | 20 g |

In 1 liter of Reverse osmosis water and autoclaved at 121°C for 15 minutes

4. Microbial Transformation Media

- | | |
|---|-----|
| - Glucose | 5 g |
| - Peptone | 1 g |
| - Yeast extract | 1 g |
| - Beef extract | 1 g |
| - Dipotassium hydrogen phosphate (K_2HPO_4) | 2 g |
| - Potassium dihydrogen phosphate (KH_2PO_4) | 2 g |

In 1 liter of Reverse osmosis water and autoclaved at 121°C for 15 minutes

5. Transform medium III: 0.05 M Phosphate Buffer pH 7.0

- | | |
|---|--------|
| - 0.2 M Sodium dihydrogen phosphate (NaH_2PO_4) | 78 ml |
| - 0.2 M Disodium hydrogen phosphate (Na_2HPO_4) | 122 ml |

Adjust volume to 800 ml with distilled water

6. LB Broth

- | | |
|--------------------------|------|
| - Tryptone peptone | 10 g |
| - Yeast extract | 5 g |
| - Sodium chloride (NaCl) | 5 g |

In 1 liter of Reverse osmosis water and autoclaved at 121°C for 15 minutes

7. LB Agar

- | | |
|--------------------------|------|
| - Tryptone peptone | 10 g |
| - Yeast extract | 5 g |
| - Sodium chloride (NaCl) | 5 g |

In 1 liter of Reverse osmosis water and autoclaved at 121°C for 15 minutes

8. Nutrient broth (NB)

- Gelatin peptone 5 g
- Beef extract 3 g

In 1 liter of Reverse osmosis water and autoclaved at 121°C for 15 minutes

9. Nutrient Agar (NA)

- Agar 20 g
- Gelatin peptone 5 g
- Beef extract 3 g

In 1 liter of Reverse osmosis water and autoclaved at 121°C for 15 minutes

ARTEMISININ REAGENT (*P*-ANISALDEHYDE)

Add 2.5 ml of anisaldehyde to 2.5 ml of concentrated sulfuric acid (H₂SO₄).

Then, add 45 ml of ethanol 95% and 1 ml of acetic acid to the mixture.

APPENDIX B

Table B1 Calculation LD₅₀ of L929 cell line treated with deoxyartemisinin
(Experiment 1)

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	4.059	3.623	3.516	3.733	0.288
Negative	0.076	0.076	0.085	0.079	0.005
2.5	0.106	0.113	0.106	0.108	0.004
1	1.698	1.222	1.865	1.595	0.334
0.75	2.322	2.712	1.46	2.165	0.641
0.5	1.962	2.259	2.258	2.160	0.171
0.1	2.515	3.235	3.274	3.008	0.427
0.01	3.978	3.395	3.178	3.517	0.414
0.0075	2.989	3.016	3.071	3.025	0.042
0.001	2.914	2.795	2.972	2.894	0.090
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.404	1.477	1.154	1.345	0.169
Negative	0.055	0.057	0.059	0.057	0.002
2.5	0.065	0.072	0.066	0.068	0.004
1	0.509	0.348	0.605	0.487	0.130
0.75	0.693	0.872	0.488	0.684	0.192
0.5	0.528	0.731	0.704	0.654	0.110
0.1	0.77	1.018	1.016	0.935	0.143
0.01	1.271	1.011	0.967	1.083	0.164
0.0075	0.975	0.943	0.938	0.952	0.020
0.001	1.048	0.89	0.946	0.961	0.080

Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	2.655	2.146	2.362	2.388	0.255
Negative	0.021	0.019	0.026	0.022	0.004
2.5	0.041	0.041	0.04	0.041	0.001
1	1.189	0.874	1.26	1.108	0.205
0.75	1.629	1.84	0.972	1.480	0.453
0.5	1.434	1.528	1.554	1.505	0.063
0.1	1.745	2.217	2.258	2.073	0.285
0.01	2.707	2.384	2.211	2.434	0.252
0.0075	2.014	2.073	2.133	2.073	0.060
0.001	1.866	1.905	2.026	1.932	0.083
Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	111.181	89.866	98.911	99.986	10.698
Negative	0.879	0.796	1.089	0.921	0.151
2.5	1.717	1.717	1.675	1.703	0.024
1	49.791	36.600	52.764	46.385	8.603
0.75	68.216	77.052	40.704	61.991	18.957
0.5	60.050	63.987	65.075	63.037	2.644
0.1	73.074	92.839	94.556	86.823	11.938
0.01	113.358	99.832	92.588	101.926	10.542
0.0075	84.338	86.809	89.322	86.823	2.492
0.001	78.141	79.774	84.841	80.918	3.494
IC ₅₀	1.599	1.597	1.619	1.605	0.012

Table B2 Calculation LD₅₀ of L929 cell line treated with deoxyartemisinin
(Experiment 2)

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	0.735	0.849		0.792	
2.5	0.090	0.100	0.110	0.100	0.010
1	1.159	0.813	0.779	0.917	0.210
0.75	0.626	0.689	0.774	0.696	0.074
0.5	1.134	0.824	0.992	0.983	0.155
0.25	0.735	0.885	0.938	0.853	0.105
0.1	1.000	1.100	1.214	1.105	0.107
0.05	1.018	0.813	0.659	0.830	0.180
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.278	0.317		0.298	
2.5	0.061	0.066	0.067	0.065	0.003
1	0.427	0.284	0.309	0.340	0.076
0.75	0.263	0.240	0.285	0.263	0.023
0.5	0.380	0.315	0.351	0.349	0.033
0.25	0.303	0.330	0.351	0.328	0.024
0.1	0.321	0.450	0.444	0.405	0.073
0.05	0.387	0.328	0.267	0.327	0.060
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.457	0.532		0.495	
2.5	0.029	0.034	0.043	0.035	0.007
1	0.732	0.529	0.470	0.577	0.137
0.75	0.363	0.449	0.489	0.434	0.064
0.5	0.754	0.509	0.641	0.635	0.123
0.25	0.432	0.555	0.587	0.525	0.082
0.1	0.679	0.650	0.770	0.700	0.063
0.05	0.631	0.485	0.392	0.503	0.120
Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	92.323	107.475		99.899	
2.5	5.859	6.869	8.687	7.138	1.433
1	147.879	106.869	94.949	116.566	27.765
0.75	73.333	90.707	98.788	87.609	13.007
0.5	152.323	102.828	129.495	128.215	24.772
0.25	87.273	112.121	118.586	105.993	16.532
0.1	137.172	131.313	155.556	141.347	12.649
0.05	127.475	97.980	79.192	101.549	24.338
IC ₅₀	1.775	1.287	1.516	1.526	0.244

Table B3 Calculation LD₅₀ of L929 cell line treated with artemisinin
(Experiment 1)

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	3.392	3.296	3.274	3.321	0.063
Negative	0.094	0.076	0.078	0.083	0.010
2.5	0.649	1.04	1.49	1.060	0.421
1	1.277	1.43	1.442	1.383	0.092
0.75	1.877	1.453	1.856	1.729	0.239
0.25	2.063	2.926	2.573	2.521	0.434
0.075	2.463	2.527	2.676	2.555	0.045
0.05	2.735	2.5	2.427	2.554	0.166
0.025	3.083	2.722	2.656	2.820	0.255
0.01	3.381	2.906	2.609	2.965	0.389
0.0075	2.736	3.504	3.025	3.088	0.388
0.005	3.338	2.909	3.009	3.085	0.224
0.0025	2.322	2.668	2.654	2.548	0.196
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.064	1.031	1.024	1.040	0.021
Negative	0.06	0.054	0.054	0.056	0.003
2.5	0.248	0.38	0.755	0.461	0.263
1	0.415	0.451	0.454	0.440	0.022
0.75	0.549	0.444	0.596	0.530	0.078
0.25	0.625	0.954	0.79	0.790	0.165
0.075	0.745	0.816	0.711	0.757	0.054
0.05	0.796	0.824	0.764	0.795	0.030
0.025	0.839	0.973	0.834	0.882	0.079
0.01	1.041	0.888	0.764	0.898	0.139
0.0075	0.862	0.94	0.843	0.882	0.051
0.005	0.991	0.899	0.912	0.934	0.050
0.0025	0.742	0.805	0.831	0.793	0.046

Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	2.328	2.265	2.25	2.281	0.041
Negative	0.034	0.022	0.024	0.027	0.006
2.5	0.401	0.66	0.735	0.599	0.175
1	0.862	0.979	0.988	0.943	0.070
0.75	1.328	1.009	1.26	1.199	0.168
0.5	1.49	2.14	1.201	1.610	0.481
0.25	1.438	1.972	1.783	1.731	0.271
0.1	1.078	0.996	0.894	0.989	0.092
0.075	1.718	1.711	1.965	1.798	0.145
0.05	1.939	1.676	1.663	1.759	0.156
0.025	2.244	1.749	1.822	1.938	0.267
0.01	2.34	2.018	1.845	2.068	0.251
0.0075	1.874	2.564	2.182	2.207	0.346
0.005	2.347	2.01	2.097	2.151	0.175
0.0025	1.58	1.863	1.823	1.755	0.153
0.001	1.643	1.748	2.228	1.873	0.312
Concentration (mg/ml)	% Viability				
	1	2	3	Mean	SD
Positive	102.060	99.299	98.641	100.000	1.814
Negative	1.491	0.964	1.052	1.169	0.282
2.5	17.580	28.935	32.223	26.246	7.683
1	37.790	42.920	43.314	41.342	3.082
0.75	58.220	44.235	55.239	52.565	7.366
0.5	65.322	93.819	52.652	70.598	21.084
0.25	63.043	86.453	78.167	75.888	11.871
0.1	47.260	43.665	39.193	43.373	4.041
0.075	75.318	75.011	86.146	78.825	6.342
0.05	85.007	73.477	72.907	77.130	6.827
0.025	98.378	76.677	79.877	84.977	11.715
0.01	102.587	88.470	80.886	90.647	11.013
0.0075	82.157	112.407	95.660	96.741	15.154
0.005	102.893	88.119	91.933	94.315	7.670
0.0025	69.268	81.675	79.921	76.955	6.714
0.001	72.030	76.633	97.676	82.113	13.673
IC ₅₀	1.078	0.902	1.197	1.059	0.148

Table B4 Calculation LD₅₀ of L929 cell line treated with artemisinin
(Experiment 2)

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	0.735	0.849		0.792	
2.5	0.594	0.496	0.471	0.520	0.065
1	0.436	0.307	0.331	0.358	0.069
0.75	0.563	0.565	0.534	0.554	0.017
0.5	0.949	0.774	0.742	0.822	0.111
0.25	0.468	0.460	0.495	0.474	0.018
0.1	0.666	0.671	0.747	0.695	0.045
0.05	0.862	0.727	0.811	0.800	0.068
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.278	0.317		0.298	
2.5	0.194	0.200	0.185	0.193	0.008
1	0.176	0.141	0.140	0.152	0.021
0.75	0.189	0.217	0.173	0.193	0.022
0.5	0.288	0.225	0.237	0.250	0.033
0.25	0.175	0.184	0.203	0.187	0.014
0.1	0.237	0.247	0.274	0.253	0.019
0.05	0.320	0.262	0.287	0.290	0.029
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.457	0.532		0.495	
2.5	0.400	0.296	0.286	0.327	0.063
1	0.260	0.166	0.191	0.206	0.049
0.75	0.374	0.348	0.361	0.361	0.013
0.5	0.661	0.549	0.505	0.572	0.080
0.25	0.293	0.276	0.292	0.287	0.010
0.1	0.429	0.424	0.473	0.442	0.027
0.05	0.542	0.465	0.524	0.510	0.040
Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	92.323	107.475		99.899	
2.5	80.808	59.798	57.778	66.128	12.753
1	52.525	33.535	38.586	41.549	9.836
0.75	75.556	70.303	72.929	72.929	2.626
0.5	133.535	110.909	102.020	115.488	16.249
0.25	59.192	55.758	58.990	57.980	1.927
0.1	86.667	85.657	95.556	89.293	5.447
0.05	109.495	93.939	105.859	103.098	8.137
IC ₅₀	0.915	1.236	1.127	1.093	0.163

Table B5 Calculation LD₅₀ of L929 cell line treated with doxorubicin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	3.621	3.617	3.866	3.701	0.143
Negative	0.08	0.081	0.09	0.084	0.006
0.01	0.275	0.312	0.274	0.287	0.022
0.0075	0.298	0.391	0.38	0.356	0.051
0.005	0.388	0.463	0.486	0.446	0.051
0.0025	0.783	1.008	1.12	0.970	0.172
0.001	1.529	1.612	1.797	1.646	0.137
0.00075	1.983	1.882	1.742	1.869	0.121
0.0005	2.061	1.778	2.005	1.948	0.150
0.00025	2.274	2.301	2.398	2.324	0.065
0.0001	2.515	1.803	2.672	2.330	0.463
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.116	1.104	1.273	1.164	0.094
Negative	0.058	0.06	0.06	0.059	0.001
0.01	0.113	0.124	0.113	0.117	0.006
0.0075	0.122	0.147	0.142	0.137	0.013
0.005	0.149	0.168	0.183	0.167	0.017
0.0025	0.264	0.313	0.383	0.320	0.060
0.001	0.462	0.541	0.55	0.518	0.048
0.00075	0.583	0.573	0.556	0.571	0.014
0.0005	0.653	0.556	0.585	0.598	0.050
0.00025	0.782	0.694	0.712	0.729	0.046
0.0001	0.828	0.615	0.818	0.754	0.120
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	2.505	2.513	2.593	2.537	0.049
Negative	0.022	0.021	0.03	0.024	0.005
0.01	0.162	0.188	0.161	0.170	0.015
0.0075	0.176	0.244	0.238	0.219	0.038
0.005	0.239	0.295	0.303	0.279	0.035
0.0025	0.519	0.695	0.737	0.650	0.116
0.001	1.067	1.071	1.247	1.128	0.103
0.00075	1.4	1.309	1.186	1.298	0.107
0.0005	1.408	1.222	1.42	1.350	0.111
0.00025	1.492	1.607	1.686	1.595	0.098
0.0001	1.687	1.188	1.854	1.576	0.347

Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	98.739	99.054	102.207	100.000	1.918
Negative	0.867	0.828	1.182	0.959	0.194
0.01	6.385	7.410	6.346	6.714	0.603
0.0075	6.937	9.618	9.381	8.645	1.484
0.005	9.421	11.628	11.943	10.997	1.375
0.0025	20.457	27.395	29.050	25.634	4.559
0.001	42.058	42.215	49.153	44.475	4.052
0.00075	55.183	51.596	46.748	51.176	4.233
0.0005	55.499	48.167	55.972	53.212	4.376
0.00025	58.810	63.343	66.456	62.870	3.845
0.0001	66.496	46.827	73.078	62.134	13.659
IC₅₀	0.00181	0.00164	0.00161	0.00169	0.00011

Table B6 Calculation IC₅₀ of B16F10 cell line treated with deoxyartemisinin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	2.328	2.934	2.751	2.671	0.311
Negative	0.119	0.117	0.121	0.119	0.002
2.5	0.307	0.295	0.362	0.321	0.036
1	0.762	0.885	0.161	0.603	0.387
0.75	1.885	1.433	0.902	1.407	0.492
0.5	1.124	1.519	1.429	1.357	0.207
0.1	2.826	2.937	3.895	3.219	0.588
0.01	3.102	3.284	3.577	3.321	0.240
0.0075	2.549	2.933	2.984	2.822	0.238
0.001	3.324	3.11	3.422	3.285	0.160
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.773	1.057	1.163	0.998	0.202
Negative	0.073	0.084	0.075	0.077	0.006
2.5	0.152	0.142	0.177	0.157	0.018
1	0.292	0.364	0.093	0.250	0.140
0.75	0.679	0.539	0.43	0.549	0.125
0.5	0.435	0.711	0.634	0.593	0.142
0.1	1.285	1.297	1.545	1.376	0.147
0.01	1.325	1.294	1.533	1.384	0.130
0.0075	1.219	1.142	1.138	1.166	0.046
0.001	1.261	1.244	1.376	1.294	0.072
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.555	1.877	1.588	1.673	0.177
Negative	0.046	0.033	0.046	0.042	0.008
2.5	0.155	0.153	0.185	0.164	0.018
1	0.47	0.521	0.068	0.353	0.248
0.75	1.206	0.894	0.472	0.857	0.368
0.5	0.689	0.808	0.795	0.764	0.065
0.1	1.541	1.64	2.35	1.844	0.441
0.01	1.777	1.99	2.044	1.937	0.141
0.0075	1.33	1.791	1.846	1.656	0.283
0.001	2.063	1.866	2.046	1.992	0.109

Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	92.947	112.194	94.919	100.020	10.589
Negative	2.750	1.973	2.750	2.491	0.449
2.5	9.265	9.145	11.058	9.823	1.071
1	28.093	31.142	4.065	21.100	14.832
0.75	72.086	53.437	28.213	51.245	22.019
0.5	41.184	48.296	47.519	45.666	3.902
0.1	92.110	98.027	140.466	110.201	26.377
0.01	106.216	118.948	122.176	115.780	8.438
0.0075	79.498	107.053	110.341	98.964	16.938
0.001	123.311	111.536	122.295	119.048	6.525
IC ₅₀	0.595	0.637	0.523	0.585	0.058

Table B7 Calculation IC₅₀ of B16F10 cell line treated with artemisinin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	2.328	2.934	2.751	2.671	0.311
Negative	0.119	0.117	0.121	0.119	0.002
2.5	0.566	1.07	0.819	0.818	0.252
0.25	2.551	2.471	2.155	2.392	0.209
0.075	2.261	2.225	2.015	2.167	0.133
0.05	2.118	2.469	2.234	2.274	0.179
0.025	2.308	2.528	2.174	2.337	0.179
0.01	2.69	2.488	2.309	2.496	0.191
0.005	2.792	2.91	2.534	2.745	0.192
0.0025	3.552	3.102	2.736	3.130	0.409
0.001	2.977	3.274	3.071	3.107	0.152
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.773	1.057	1.163	0.998	0.202
Negative	0.073	0.084	0.075	0.077	0.006
2.5	0.219	0.38	0.313	0.304	0.081
0.25	0.92	1.007	0.999	0.975	0.048
0.075	0.839	0.796	0.927	0.854	0.067
0.05	0.753	0.977	1.088	0.939	0.171
0.025	0.874	0.967	0.859	0.900	0.059
0.01	1.027	0.941	0.924	0.964	0.055
0.005	0.983	1.121	1.137	1.080	0.085
0.0025	1.334	1.094	1.182	1.203	0.121
0.001	1.12	1.177	1.214	1.170	0.047
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.555	1.877	1.588	1.673	0.177
Negative	0.046	0.033	0.046	0.042	0.008
2.5	0.347	0.69	0.506	0.514	0.172
0.25	1.631	1.464	1.156	1.417	0.241
0.075	1.422	1.429	1.088	1.313	0.195
0.05	1.365	1.492	1.146	1.334	0.175
0.025	1.434	1.561	1.315	1.437	0.123
0.01	1.663	1.547	1.385	1.532	0.140
0.005	1.809	1.789	1.397	1.665	0.232
0.0025	2.218	2.008	1.554	1.927	0.339
0.001	1.857	2.097	1.857	1.937	0.139

Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	92.947	112.194	94.919	100.020	10.589
Negative	2.750	1.973	2.750	2.491	0.449
2.5	20.741	41.243	30.245	30.743	10.260
0.25	97.490	87.507	69.097	84.698	14.403
0.075	84.997	85.415	65.033	78.482	11.649
0.05	81.590	89.181	68.500	79.757	10.462
0.025	85.714	93.305	78.601	85.874	7.353
0.01	99.402	92.469	82.785	91.552	8.346
0.005	108.129	106.934	83.503	99.522	13.886
0.0025	132.576	120.024	92.887	115.162	20.286
0.001	110.998	125.344	110.998	115.780	8.282
IC₅₀	0.934	0.884	0.795	0.871	0.070

Table B8 Calculation IC₅₀ of B16F10 cell line treated with doxorubicin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	3.156	3.109	3.231	3.165	0.062
Negative	0.103	0.109	0.103	0.105	0.003
0.01	0.216	0.247	0.396	0.286	0.096
0.005	0.311	0.424	0.225	0.320	0.100
0.001	0.516	0.767	0.556	0.613	0.135
0.00075	1.794	1.354	1.266	1.471	0.283
0.0005	2.441	2.476	2.152	2.356	0.178
0.00025	2.878	2.457	1.943	2.426	0.468
0.0001	2.724	2.827	2.126	2.559	0.379
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.144	1.144	1.403	1.230	0.150
Negative	0.07	0.07	0.067	0.069	0.002
0.01	0.115	0.119	0.213	0.149	0.055
0.005	0.146	0.237	0.104	0.162	0.068
0.001	0.229	0.289	0.2	0.239	0.045
0.00075	0.617	0.426	0.458	0.500	0.102
0.0005	0.903	0.902	0.794	0.866	0.063
0.00025	1.024	0.866	0.726	0.872	0.149
0.0001	0.931	1.112	0.793	0.945	0.160
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	2.012	1.965	1.828	1.935	0.096
Negative	0.033	0.039	0.036	0.036	0.003
0.01	0.101	0.128	0.183	0.137	0.042
0.005	0.165	0.187	0.121	0.158	0.034
0.001	0.287	0.478	0.356	0.374	0.097
0.00075	1.177	0.928	0.808	0.971	0.188
0.0005	1.538	1.574	1.358	1.490	0.116
0.00025	1.854	1.591	1.217	1.554	0.320
0.0001	1.793	1.715	1.333	1.614	0.246

Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	103.979	101.550	94.470	100.000	4.940
Negative	1.705	2.016	1.860	1.860	0.155
0.01	5.220	6.615	9.457	7.097	2.160
0.005	8.527	9.664	6.253	8.148	1.737
0.001	14.832	24.703	18.398	19.311	4.998
0.00075	60.827	47.959	41.757	50.181	9.727
0.0005	79.483	81.344	70.181	77.003	5.981
0.00025	95.814	82.222	62.894	80.310	16.543
0.0001	92.661	88.630	68.889	83.394	12.722
IC₅₀	0.000626	0.000627	0.000731	0.00066	0.00006

Table B9 Calculation IC₅₀ of A549 cell line treated with deoxyartemisinin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	1.686	2.572	2.128	2.129	0.443
Negative	0.067	0.065	0.057	0.063	0.005
2.5	0.091	0.094	0.086	0.090	0.004
1	0.085	0.089	0.139	0.104	0.030
0.75	0.783	0.68	0.515	0.659	0.135
0.25	0.993	1.453	1.314	1.253	0.236
0.1	1.342	1.383	1.835	1.520	0.274
0.01	1.892	1.841	2.19	1.974	0.189
0.0075	1.706	2.234	2.458	2.133	0.386
0.005	1.609	2.051	1.874	1.845	0.222
0.0025	1.491	1.936	1.717	1.715	0.223
0.001	1.988	1.742	1.782	1.837	0.132
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.816	0.996	0.919	0.910	0.090
Negative	0.055	0.055	0.052	0.054	0.002
2.5	0.061	0.063	0.061	0.062	0.001
1	0.063	0.065	0.077	0.068	0.008
0.75	0.385	0.321	0.236	0.314	0.075
0.25	0.431	0.606	0.623	0.553	0.106
0.1	0.58	0.543	0.744	0.622	0.107
0.01	0.897	0.803	0.883	0.861	0.051
0.0075	0.837	0.943	0.953	0.911	0.064
0.005	0.663	0.855	0.885	0.801	0.120
0.0025	0.688	0.806	0.672	0.722	0.073
0.001	0.874	0.79	0.812	0.825	0.044
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.87	1.576	1.209	1.218	0.353
Negative	0.012	0.01	0.005	0.009	0.004
2.5	0.03	0.031	0.025	0.029	0.003
1	0.022	0.024	0.062	0.036	0.023
0.75	0.398	0.359	0.279	0.345	0.061
0.25	0.562	0.847	0.691	0.700	0.143
0.1	0.762	0.84	1.091	0.898	0.172
0.01	0.995	1.038	1.307	1.113	0.169
0.0075	0.869	1.291	1.505	1.222	0.324
0.005	0.946	1.196	0.989	1.044	0.134
0.0025	0.803	1.13	1.045	0.993	0.170
0.001	1.114	0.952	0.97	1.012	0.089

Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	71.429	129.392	99.261	100.027	28.990
Negative	0.985	0.821	0.411	0.739	0.296
2.5	2.463	2.545	2.053	2.354	0.264
1	1.806	1.970	5.090	2.956	1.850
0.75	32.677	29.475	22.906	28.352	4.981
0.25	46.141	69.540	56.732	57.471	11.717
0.1	62.562	68.966	89.573	73.700	14.114
0.01	81.691	85.222	107.307	91.407	13.883
0.0075	71.346	105.993	123.563	100.301	26.570
0.005	77.668	98.194	81.199	85.687	10.974
0.0025	65.928	92.775	85.796	81.500	13.930
0.001	91.461	78.161	79.639	83.087	7.290
IC₅₀	0.339	0.409	0.433	0.394	0.049

Table B10 Calculation IC₅₀ of A549 cell line treated with artemisinin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	2.085	1.861	1.882	1.943	0.124
Negative	0.061	0.078	0.057	0.065	0.011
2.5	0.453	0.424	0.413	0.430	0.021
1	0.57	0.59	0.541	0.580	0.014
0.75	0.563	0.587	0.767	0.639	0.111
0.5	0.989	1.074	1.092	1.052	0.055
0.25	1.115	1.146	0.967	1.076	0.096
0.075	0.997	1.18	1.178	1.088	0.128
0.05	1.046	1.507	1.689	1.368	0.455
0.0075	1.534	1.581	1.041	1.385	0.299
0.005	1.366	1.117	1.049	1.177	0.167
0.0025	1.552	1.44	1.149	1.380	0.208
0.001	1.546	1.561	1.177	1.428	0.218
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.926	0.958	0.74	0.875	0.118
Negative	0.054	0.058	0.052	0.055	0.003
2.5	0.19	0.193	0.177	0.192	0.009
1	0.246	0.254	0.255	0.250	0.005
0.75	0.26	0.283	0.332	0.272	0.037
0.5	0.417	0.458	0.464	0.438	0.026
0.25	0.449	0.491	0.395	0.470	0.048
0.075	0.417	0.498	0.474	0.458	0.042
0.05	0.45	0.623	0.745	0.537	0.148
0.0075	0.604	0.863	0.511	0.734	0.182
0.005	0.657	0.546	0.502	0.602	0.080
0.0025	0.725	0.685	0.565	0.705	0.083
0.001	0.704	0.783	0.522	0.744	0.134

Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.159	0.903	1.142	1.068	0.143
Negative	0.007	0.02	0.005	0.011	0.008
2.5	0.263	0.231	0.236	0.247	0.017
1	0.324	0.336	0.286	0.330	0.026
0.75	0.303	0.304	0.435	0.304	0.076
0.5	0.572	0.616	0.628	0.594	0.029
0.25	0.666	0.655	0.572	0.661	0.051
0.075	0.58	0.682	0.704	0.631	0.066
0.05	0.596	0.884	0.944	0.740	0.186
0.0075	0.93	0.718	0.53	0.824	0.200
0.005	0.709	0.571	0.547	0.640	0.087
0.0025	0.827	0.755	0.584	0.791	0.125
0.001	0.842	0.778	0.655	0.810	0.095
Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	108.521	84.551	106.929	100.000	13.403
Negative	0.655	1.873	0.468	0.999	0.763
2.5	24.625	21.629	22.097	23.127	1.612
1	30.337	31.461	26.779	30.899	2.444
0.75	28.371	28.464	40.730	28.418	7.109
0.5	53.558	57.678	58.801	55.618	2.761
0.25	62.360	61.330	53.558	61.845	4.812
0.075	54.307	63.858	65.918	59.082	6.195
0.05	55.805	82.772	88.390	69.288	17.419
0.0075	87.079	67.228	49.625	77.154	18.738
0.005	66.386	53.464	51.217	59.925	8.186
0.0025	77.434	70.693	54.682	74.064	11.687
0.001	78.839	72.846	61.330	75.843	8.899
IC ₅₀	0.624	0.474	0.670	0.589	0.102

Table B11 Calculation IC₅₀ of A549 cell line treated with doxorubicin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	1.896	2.34	1.983	2.073	0.235
Negative	0.067	0.061	0.066	0.065	0.003
0.005	0.554	0.516	0.509	0.535	0.027
0.0025	0.38	0.507	0.678	0.444	0.090
0.001	1.331	1.388	1.366	1.362	0.029
0.00075	1.596	1.281	1.501	1.459	0.162
0.0005	1.610	1.622	1.765	1.666	0.086
0.00025	1.979	1.829	1.624	1.811	0.178
0.0001	1.999	2.025	1.951	1.992	0.038
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.867	1.028	0.986	0.960	0.084
Negative	0.055	0.054	0.053	0.054	0.001
0.005	0.232	0.229	0.206	0.231	0.002
0.0025	0.176	0.227	0.285	0.202	0.036
0.001	0.517	0.562	0.544	0.541	0.023
0.00075	0.612	0.486	0.584	0.561	0.066
0.0005	0.646	0.635	0.66	0.647	0.013
0.00025	0.771	0.732	0.643	0.715	0.066
0.0001	0.953	0.844	0.779	0.859	0.088
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.029	1.312	0.997	1.113	0.173
Negative	0.012	0.007	0.013	0.011	0.003
0.005	0.322	0.287	0.303	0.305	0.025
0.0025	0.204	0.28	0.393	0.242	0.054
0.001	0.814	0.826	0.822	0.821	0.006
0.00075	0.984	0.795	0.917	0.899	0.096
0.0005	0.964	0.987	1.105	1.019	0.076
0.00025	1.208	1.097	0.981	1.095	0.114
0.0001	1.046	1.181	1.172	1.133	0.075

Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	92.453	117.880	89.578	99.970	15.577
Negative	1.078	0.629	1.168	0.958	0.289
0.005	28.931	25.786	27.224	27.358	2.224
0.0025	18.329	25.157	35.310	21.743	4.828
0.001	73.136	74.214	73.854	73.735	0.549
0.00075	88.410	71.429	82.390	80.743	8.610
0.0005	86.613	88.679	99.281	91.524	6.797
0.00025	108.535	98.562	88.140	98.413	10.198
0.0001	93.980	106.110	105.301	101.797	6.782
IC ₅₀	0.00146	0.00176	0.00248	0.00190	0.00052

Table B12 Calculation IC₅₀ of HT-29 cell line treated with deoxyartemisinin
(Experiment 1)

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	1.701	2.432	2.306	2.146	0.391
Negative	0.089	0.084	0.086	0.086	0.003
2.5	0.356	0.229	0.375	0.320	0.079
1	1.712	2.392	2.334	2.146	0.377
0.75	2.235	2.017	2.716	2.323	0.358
0.5	2.327	2.46	2.699	2.495	0.189
0.25	2.112	2.053	3.3	2.488	0.704
0.01	3.316	3.423	4.018	3.586	0.378
0.0075	3.137	3.075	2.921	3.044	0.111
0.001	3.249	3.519	3.513	3.427	0.154
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.647	0.881	0.908	0.812	0.144
Negative	0.058	0.057	0.059	0.058	0.001
2.5	0.126	0.098	0.133	0.119	0.019
1	0.541	0.724	0.686	0.650	0.097
0.75	0.718	0.656	0.758	0.711	0.051
0.5	0.691	0.725	0.76	0.725	0.035
0.25	0.655	0.658	1.057	0.790	0.231
0.01	1.172	1.026	1.569	1.256	0.281
0.0075	1.006	0.95	1.093	1.016	0.072
0.001	1.108	1.197	1.185	1.163	0.048
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.054	1.551	1.398	1.334	0.255
Negative	0.031	0.027	0.027	0.028	0.002
2.5	0.23	0.131	0.242	0.201	0.061
1	1.171	1.668	1.648	1.496	0.281
0.75	1.517	1.361	1.958	1.612	0.310
0.5	1.636	1.735	1.939	1.770	0.155
0.25	1.457	1.395	2.243	1.698	0.473
0.01	2.144	2.397	2.449	2.330	0.163
0.0075	2.131	2.125	1.828	2.028	0.173
0.001	2.141	2.322	2.328	2.264	0.106

Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	79.010	116.267	104.798	100.025	19.081
Negative	2.324	2.024	2.024	2.124	0.173
2.5	17.241	9.820	18.141	15.067	4.567
1	87.781	125.037	123.538	112.119	21.091
0.75	113.718	102.024	146.777	120.840	23.211
0.5	122.639	130.060	145.352	132.684	11.582
0.25	109.220	104.573	168.141	127.311	35.436
0.01	160.720	179.685	183.583	174.663	12.231
0.0075	159.745	159.295	137.031	152.024	12.986
0.001	160.495	174.063	174.513	169.690	7.967
IC ₅₀	2.034	1.668	1.246	1.649	0.394

Table B13 Calculation IC₅₀ of HT-29 cell line treated with deoxyartemisinin
(Experiment 2)

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive				1.148	
2.5	0.156	0.152	0.161	0.156	0.005
1	0.507	0.510	0.477	0.498	0.018
0.75	0.669	0.504	0.565	0.579	0.083
0.5	0.669	0.541	0.565	0.592	0.068
0.25	0.466	0.526	0.462	0.485	0.036
0.1	0.655	0.597	0.524	0.592	0.066
0.05	0.430	0.454	0.390	0.425	0.032
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive				0.463	
2.5	0.156	0.152	0.161	0.156	0.005
1	0.507	0.510	0.477	0.498	0.018
0.75	0.669	0.504	0.565	0.579	0.083
0.5	0.669	0.541	0.565	0.592	0.068
0.25	0.466	0.526	0.462	0.485	0.036
0.1	0.655	0.597	0.524	0.592	0.066
0.05	0.430	0.454	0.390	0.425	0.032
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive				0.685	
2.5	0.264	0.236	0.250	0.250	0.014
1	0.638	0.615	0.632	0.628	0.012
0.75	0.963	0.988	0.753	0.901	0.129
0.5	1.019	0.889	0.993	0.967	0.069
0.25	0.675	0.960	0.863	0.833	0.145
0.1	1.044	0.832	0.839	0.905	0.120
0.05	0.534	0.645	0.722	0.634	0.095
Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive				100.000	
2.5	38.540	34.453	36.496	36.496	2.044
1	93.139	89.781	92.263	91.727	1.742
0.75	140.584	144.234	109.927	131.582	18.842
0.5	148.759	129.781	144.964	141.168	10.042
0.25	98.540	140.146	125.985	121.557	21.153
0.1	152.409	121.460	122.482	132.117	17.581
0.05	77.956	94.161	105.401	92.506	13.797
IC ₅₀	1.144	1.211	1.193	1.183	0.035

Table B14 Calculation IC₅₀ of HT-29 cell line treated with artemisinin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	3.624	2.506	2.201	2.777	0.749
Negative	0.085	0.078	0.078	0.080	0.004
2.5	0.751	1.040	1.099	0.963	0.186
0.1	1.064	1.072	0.965	1.034	0.060
0.075	1.510	1.876	1.770	1.719	0.188
0.025	2.060	1.900	2.237	2.066	0.169
0.0075	2.524	2.061	2.115	2.233	0.253
0.005	2.069	2.378	2.285	2.244	0.159
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	1.259	0.899	0.818	0.992	0.235
Negative	0.057	0.053	0.057	0.056	0.002
2.5	0.264	0.302	0.323	0.296	0.030
0.1	0.413	0.461	0.403	0.426	0.031
0.075	0.551	0.622	0.549	0.574	0.042
0.025	0.682	0.752	0.789	0.741	0.054
0.0075	0.949	0.744	0.842	0.845	0.103
0.005	0.700	0.867	0.808	0.792	0.085
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	2.365	1.607	1.383	1.785	0.515
Negative	0.028	0.025	0.021	0.025	0.004
2.5	0.487	0.738	0.776	0.667	0.157
0.1	0.651	0.611	0.562	0.608	0.045
0.075	0.959	1.254	1.221	1.145	0.162
0.025	1.378	1.148	1.448	1.325	0.157
0.0075	1.575	1.317	1.273	1.388	0.163
0.005	1.369	1.511	1.477	1.452	0.074
Concentration (mg/ml)	% Viability				
	1	2	3	Mean	SD
Positive	132.493	90.028	77.479	100.000	28.831
Negative	1.569	1.401	1.176	1.382	0.197
2.5	27.283	41.345	43.473	37.367	8.798
0.1	36.471	34.230	31.485	34.062	2.497
0.075	53.725	70.252	68.403	64.127	9.055
0.025	77.199	64.314	81.120	74.211	8.793
0.0075	88.235	73.782	71.317	77.778	9.140
0.005	76.695	84.650	82.745	81.363	4.154
IC ₅₀	0.080	0.082	0.079	0.080	0.001

Table B15 Calculation IC₅₀ of HT-29 cell line treated with doxorubicin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	1.211	1.313	1.046	1.190	0.135
Negative	0.094	0.094	0.095	0.094	0.001
0.01	0.504	0.408	0.475	0.462	0.049
0.0025	0.587	0.546	0.597	0.577	0.027
0.0005	0.749	0.747	0.755	0.750	0.004
0.00025	0.716	0.621	0.604	0.647	0.060
0.0001	0.677	0.67	0.665	0.671	0.006
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.415	0.43	0.37	0.405	0.031
Negative	0.062	0.06	0.063	0.062	0.002
0.01	0.194	0.18	0.185	0.186	0.007
0.0025	0.203	0.191	0.204	0.199	0.007
0.0005	0.254	0.268	0.253	0.258	0.008
0.00025	0.238	0.211	0.201	0.217	0.019
0.0001	0.233	0.23	0.223	0.229	0.005
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.796	0.883	0.676	0.785	0.104
Negative	0.032	0.034	0.032	0.033	0.001
0.01	0.31	0.228	0.29	0.276	0.043
0.0025	0.384	0.355	0.393	0.377	0.020
0.0005	0.495	0.479	0.502	0.492	0.012
0.00025	0.478	0.41	0.403	0.430	0.041
0.0001	0.444	0.44	0.442	0.442	0.002
Concentration (mg/ml)	% Viability				
	1	2	3	Mean	SD
Positive	101.401	112.484	86.115	100.000	13.240
Negative	4.076	4.331	4.076	4.161	0.147
0.01	39.490	29.045	36.943	35.159	5.447
0.0025	48.917	45.223	50.064	48.068	2.530
0.0005	63.057	61.019	63.949	62.675	1.502
0.00025	60.892	52.229	51.338	54.820	5.278
0.0001	56.561	56.051	56.306	56.306	0.255
IC ₅₀	0.00155	0.00224	0.00270	0.00216	0.00058

Table B16 Calculation IC₅₀ of Caco-2 cell line treated with deoxyartemisinin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	0.886	1.248	1.395	1.176	0.262
Negative	0.091	0.078	0.076	0.082	0.008
2.5	0.232	0.085	0.15	0.156	0.074
1	0.602	0.426	0.762	0.597	0.168
0.75	0.735	0.477	0.759	0.657	0.156
0.5	0.683	0.82	0.596	0.700	0.113
0.25	0.804	1.482	1.114	1.133	0.339
0.1	0.855	1.118	1.107	1.027	0.149
0.075	0.669	0.755	1.087	0.837	0.221
0.005	1.198	1.059	0.817	1.025	0.193
0.0025	1.368	0.989	0.543	0.967	0.413
0.001	1.225	1.389	0.892	1.169	0.253
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.408	0.517	0.64	0.522	0.116
Negative	0.062	0.058	0.057	0.059	0.003
2.5	0.112	0.063	0.094	0.090	0.025
1	0.276	0.22	0.337	0.278	0.059
0.75	0.313	0.247	0.353	0.304	0.054
0.5	0.336	0.376	0.288	0.333	0.044
0.25	0.384	0.591	0.481	0.485	0.104
0.1	0.379	0.484	0.499	0.454	0.065
0.075	0.331	0.368	0.493	0.397	0.085
0.005	0.566	0.542	0.399	0.502	0.090
0.0025	0.608	0.416	0.279	0.434	0.165
0.001	0.519	0.595	0.402	0.505	0.097
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.478	0.731	0.755	0.655	0.153
Negative	0.029	0.02	0.019	0.023	0.006
2.5	0.12	0.022	0.056	0.066	0.050
1	0.326	0.206	0.425	0.319	0.110
0.75	0.422	0.23	0.406	0.353	0.107
0.5	0.347	0.444	0.308	0.366	0.070
0.25	0.42	0.891	0.633	0.648	0.236
0.1	0.476	0.634	0.608	0.573	0.085
0.075	0.338	0.387	0.594	0.440	0.136
0.005	0.632	0.517	0.418	0.522	0.107
0.0025	0.76	0.573	0.264	0.532	0.250
0.001	0.706	0.794	0.49	0.663	0.156

Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	72.977	111.603	115.267	99.949	23.430
Negative	4.427	3.053	2.901	3.461	0.841
2.5	18.321	3.359	8.550	10.076	7.597
1	49.771	31.450	64.885	48.702	16.743
0.75	64.427	35.115	61.985	53.842	16.265
0.5	52.977	67.786	47.023	55.929	10.692
0.25	64.122	136.031	96.641	98.931	36.009
0.1	72.672	96.794	92.824	87.430	12.934
0.075	51.603	59.084	90.687	67.125	20.746
0.005	96.489	78.931	63.817	79.746	16.351
0.0025	116.031	87.481	40.305	81.272	38.242
0.001	107.786	121.221	74.809	101.272	23.882
IC₅₀	1.000	0.840	0.979	0.940	0.087

Table B17 Calculation IC₅₀ of Caco-2 cell line treated with artemisinin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	0.506	0.492	0.532	0.510	0.020
Negative	0.064	0.075	0.064	0.068	0.006
2.5	0.667	0.679	0.700	0.682	0.017
1	1.138	1.105	1.037	1.093	0.052
0.75	1.000	1.021	1.087	1.036	0.045
0.5	1.437	1.213	1.337	1.329	0.112
0.25	1.319	1.596	1.479	1.465	0.139
0.1	0.805	0.870	0.831	0.835	0.033
0.075	1.185	1.011	1.000	1.065	0.104
0.05	0.862	0.625	1.077	0.855	0.226
0.025	0.457	0.351	0.931	0.580	0.309
0.01	0.865	0.753	0.698	0.772	0.085
0.0075	1.333	1.469	0.835	1.212	0.334
0.005	1.036	1.238	0.804	1.026	0.217
0.0025	1.041	0.916	0.975	0.977	0.063
0.001	1.221	1.169	1.232	1.207	0.034
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.254	0.253	0.27	0.259	0.010
Negative	0.052	0.056	0.053	0.054	0.002
2.5	0.277	0.283	0.29	0.283	0.007
1	0.439	0.411	0.429	0.426	0.014
0.75	0.424	0.417	0.487	0.443	0.039
0.5	0.548	0.512	0.517	0.526	0.020
0.25	0.544	0.596	0.652	0.597	0.054
0.1	0.386	0.405	0.382	0.391	0.012
0.075	0.472	0.461	0.463	0.465	0.006
0.05	0.371	0.299	0.484	0.385	0.093
0.025	0.223	0.153	0.399	0.258	0.127
0.01	0.412	0.305	0.322	0.346	0.058
0.0075	0.516	0.626	0.386	0.509	0.120
0.005	0.471	0.487	0.354	0.437	0.073
0.0025	0.496	0.423	0.409	0.443	0.047
0.001	0.559	0.501	0.537	0.532	0.029

Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.252	0.239	0.262	0.251	0.012
Negative	0.012	0.019	0.011	0.014	0.004
2.5	0.390	0.396	0.410	0.399	0.010
1	0.699	0.694	0.608	0.667	0.051
0.75	0.576	0.604	0.600	0.593	0.015
0.5	0.889	0.701	0.820	0.803	0.095
0.25	0.775	1.000	0.827	0.867	0.118
0.1	0.419	0.465	0.449	0.444	0.023
0.075	0.713	0.550	0.537	0.600	0.098
0.05	0.491	0.326	0.593	0.470	0.135
0.025	0.234	0.198	0.532	0.321	0.183
0.01	0.453	0.448	0.376	0.426	0.043
0.0075	0.817	0.843	0.449	0.703	0.220
0.005	0.565	0.751	0.450	0.589	0.152
0.0025	0.545	0.493	0.566	0.535	0.038
0.001	0.662	0.668	0.695	0.675	0.018
Concentration (mg/ml)	%Viability				
	1	2	3	Mean	SD
Positive	100.398	95.219	104.382	100.000	4.595
Negative	4.781	7.570	4.382	5.578	1.737
2.5	155.378	157.769	163.347	158.831	4.089
1	278.486	276.494	242.231	265.737	20.381
0.75	229.482	240.637	239.044	236.388	6.033
0.5	354.183	279.283	326.693	320.053	37.889
0.25	308.765	398.406	329.482	345.551	46.931
0.1	166.932	185.259	178.884	177.025	9.304
0.075	284.064	219.124	213.944	239.044	39.074
0.05	195.618	129.880	236.255	187.251	53.679
0.025	93.227	78.884	211.952	128.021	73.039
0.01	180.478	178.486	149.801	169.588	17.165
0.0075	325.498	335.857	178.884	280.080	87.791
0.005	225.100	299.203	179.283	234.529	60.514
0.0025	217.131	196.414	225.498	213.015	14.973
0.001	263.745	266.135	276.892	268.924	7.003
IC ₅₀				Not determine	

Table B18 Calculation IC₅₀ of Caco-2 cell line treated with doxorubicin

Concentration (mg/ml)	A ₅₅₀				
	1	2	3	Mean	SD
Positive	0.502	0.584	0.505	0.530	0.038
Negative	0.064	0.068	0.068	0.067	0.002
0.01	0.637	0.712	0.386	0.578	0.139
0.0075	0.928	0.909	1.028	0.955	0.052
0.005	0.686	0.883	0.762	0.777	0.081
0.0025	1.216	1.109	0.943	1.089	0.112
0.001	0.926	0.604	0.641	0.724	0.144
0.00075	0.916	1.662	1.085	1.221	0.319
0.0005	0.904	0.683	1.022	0.870	0.141
0.00025	1.133	0.71	0.702	0.848	0.201
0.0001	1.263	1.046	0.899	1.069	0.150
Concentration (mg/ml)	A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.242	0.279	0.242	0.254	0.017
Negative	0.053	0.054	0.055	0.054	0.001
0.01	0.244	0.304	0.194	0.247	0.045
0.0075	0.369	0.356	0.411	0.379	0.023
0.005	0.315	0.378	0.294	0.329	0.036
0.0025	0.484	0.464	0.344	0.431	0.062
0.001	0.397	0.269	0.267	0.311	0.061
0.00075	0.401	0.611	0.437	0.483	0.092
0.0005	0.382	0.255	0.378	0.338	0.059
0.00025	0.467	0.301	0.279	0.349	0.084
0.0001	0.442	0.36	0.319	0.374	0.051
Concentration (mg/ml)	A ₅₅₀ -A ₆₂₀				
	1	2	3	Mean	SD
Positive	0.26	0.305	0.263	0.276	0.021
Negative	0.011	0.014	0.013	0.013	0.001
0.01	0.393	0.408	0.192	0.331	0.098
0.0075	0.559	0.553	0.617	0.576	0.029
0.005	0.371	0.505	0.468	0.448	0.057
0.0025	0.732	0.645	0.599	0.659	0.055
0.001	0.529	0.335	0.374	0.413	0.084
0.00075	0.515	1.051	0.648	0.738	0.228
0.0005	0.522	0.428	0.644	0.531	0.088
0.00025	0.666	0.409	0.423	0.499	0.118
0.0001	0.821	0.686	0.58	0.696	0.099

Concentration (mg/ml)	% Viability				
	1	2	3	Mean	SD
Positive	94.203	110.507	95.290	100.000	7.443
Negative	3.986	5.072	4.710	4.589	0.452
0.01	142.391	147.826	69.565	119.928	35.681
0.0075	202.536	200.362	223.551	208.816	10.456
0.005	134.420	182.971	169.565	162.319	20.472
0.0025	265.217	233.696	217.029	238.647	19.982
0.001	191.667	121.377	135.507	149.517	30.358
0.00075	186.594	380.797	234.783	267.391	82.568
0.0005	189.130	155.072	233.333	192.512	32.039
0.00025	241.304	148.188	153.261	180.918	42.750
0.0001	297.464	248.551	210.145	252.053	35.734
IC₅₀				Not determine	

CURRICULUM VITAE**Name**

Miss Wannipa Pipatsamut

Date of birth

February 12, 1986

Education

High school degree from Dara Academy,

Chiang Mai, Thailand

Bachelor of Science (Food Science and Technology),

Chiang Mai University, 2008

Master of Science (Biotechnology),

Chiang Mai University, 2012